Related references
Note: Only part of the references are listed.A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Tim West et al.
MOLECULAR NEURODEGENERATION (2021)
Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
Jung-Min Pyun et al.
CLINICAL INTERVENTIONS IN AGING (2021)
Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease
Shorena Janelidze et al.
JAMA NEUROLOGY (2021)
Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
Duygu Tosun et al.
BRAIN COMMUNICATIONS (2021)
The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer's disease
Giacomo Tondo et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
James D. Doecke et al.
NEUROLOGY (2020)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Andrea Vergallo et al.
ALZHEIMERS & DEMENTIA (2019)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease
Wei-Wei Li et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease
Pratishtha Chatterjee et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Akinori Nakamura et al.
NATURE (2018)
Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease
Jonathan Vogelgsang et al.
EXPERIMENTAL BRAIN RESEARCH (2018)
Tau passive immunization inhibits not only tau but also Aβ pathology
Chun-ling Dai et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Serge Gauthier et al.
LANCET (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Osama Sabri et al.
ALZHEIMERS & DEMENTIA (2015)
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Jon B. Toledo et al.
BRAIN (2015)
Aβ42 and Aβ40: similarities and differences
Tian Qiu et al.
JOURNAL OF PEPTIDE SCIENCE (2015)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Novel plasma biomarker surrogating cerebral amyloid deposition
Naoki Kaneko et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2014)
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Jon B. Toledo et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline A Systematic Review and Meta-analysis
Alain Koyama et al.
ARCHIVES OF NEUROLOGY (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Sporadic cerebral amyloid angiopathy
J. Attems et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2011)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola et al.
ARCHIVES OF NEUROLOGY (2009)
Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women
Deborah R. Gustafson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
CSF markers for incipient Alzheimer's disease
K Blennow et al.
LANCET NEUROLOGY (2003)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
A novel function of monomeric amyloid β-protein serving as an antioxidant molecule against metal-induced oxidative damage
K Zou et al.
JOURNAL OF NEUROSCIENCE (2002)
Alzheimer's disease: Genes, proteins, and therapy
DJ Selkoe
PHYSIOLOGICAL REVIEWS (2001)
Share Paper
